Objective-The present studies aimed at elucidating the role of prostaglandin E 2 receptor subtype 3 (E-prostanoid [EP] 3)
H ypertension is a major cardiovascular risk factor and a prominent worldwide health challenge. Prostaglandins are endogenous oxygenated fatty acid metabolites and play important roles in modulating arterial blood pressure (BP) and renal salt excretion. [1] [2] [3] Prostaglandin E 2 (PGE 2 ) is a major prostanoid synthesized in mouse kidney and vasculature 4 and is unique among the prostanoids in that it can activate 4 distinct G proteincoupled membrane receptors-designated E-prostanoid (EP) receptor 1 (EP1), EP2, EP3, and EP4. EP receptors exhibit characteristic tissue distribution 1, 5 and evoke receptor-specific signaling pathways. 6 The EP1 and EP3 receptors were initially defined as involved in vasoconstriction, whereas the EP2 and EP4 receptors participate in the relaxation of vascular smooth muscle. [7] [8] [9] At the cellular level, EP1 receptor activation leads to increased intracellular Ca 2+ , 10, 11 whereas EP3 receptor signals through a number of pathways, including activation of the inhibitory G protein, lead to a decrease in intracellular cAMP concentration as well as an increase in intracellular calcium. [12] [13] [14] [15] [16] Moreover, EP3 receptor could activate G 13 protein, leading to the activation of the small GTPase Rho. 17 The EP2 and EP4 receptors couple to the stimulatory G protein, leading to receptor-evoked increase of intracellular cAMP concentration. [7] [8] [9] The multiple functionally antagonistic signaling pathways evoked by PGE 2 suggest that the 4 EP receptors may act in concert to maintain BP homeostasis.
An important role for EP1 receptors in modulating angiotensin II (Ang II) effects on systemic BP was revealed in our previous study, which showed that EP1 null mice exhibited reduced BP and a blunted vasopressor response to acute and chronic infusion of Ang II. 18 Disruption of the EP2 receptor unmasked the pressor response to PGE 2 19 and was susceptible to salt-sensitive hypertension. 19 In addition, our previous study demonstrated EP2 receptor played an important role in neointimal hyperplasia after arterial injury. 20 PGE 2 may also induce vascular relaxation by EP4 receptor-mediated activation of endothelial NO synthase, 21 consistent with the observed vasodepressor effect of the EP4 agonist PGE 1 -OH in wild-type mice. 22 However, the role of EP3 receptor in regulating vascular tone and BP is only partially characterized. In the present studies, we used a mouse with targeted disruption of the EP3 gene to determine the role of the EP3 receptor in systemic hemodynamics and to examine the response to Ang II-induced hypertension. We found that EP3 gene disruption resulted in reduced basal BP and attenuated Ang II-evoked hypertension. 
Methods

Experimental Animals and Reagents
BP Measurement
Male congenic C57BL/6 mice aged 12 to 16 weeks and with 20 to 25 g body weight were used. After a 2-week training period, basal BP was measured in conscious EP3 +/+ and EP3 −/− mice using the tailcuff method as previously reported. 22 These mice were then used in chronic Ang II infusion experiments. For acute infusion studies, mice were anesthetized with 80 mg/kg ketamine and 8 mg/kg inactin intraperitoneally and placed on a temperature-controlled pad. After tracheostomy, PE-10 tubing was inserted into the right carotid artery, and BP was measured with a Cobe CDX II transducer connected to a BP analyzer (BPA 400; Micromed, Louisville, KY) as previously reported. 22 A jugular vein catheter was placed for infusion of test agents. BP was recorded for 30 to 60 minutes until stable values were obtained, and then 100 μL of test agents (sulprostone, M&B28767, PGE 2 , phenylephrine (PhE), or sodium nitroprusside) dissolved in saline were injected as a bolus via the jugular vein. For Ang II studies, Ang II dissolved in normal saline was continuously infused via the jugular vein at a rate of 75 pmol/kg per minure for 30 minutes. BP and heart rates were recorded continuously on a thermal printer or as a computerized data record.
Ang II-Dependent Chronic Hypertension
Chronic Ang II-dependent hypertension was induced in EP3 +/+ and EP3 −/− mice as previously described. 23 Briefly, Ang II (1000 ng/kg per minute) dissolved in sterile saline was infused using an osmotic minipump (Alzet model 2004; Alza Corp) inserted subcutaneously during chloral hydrate anesthesia (10%). After 3 days of full recovery from the surgery, systolic BP (SBP) and heart rates were recorded every other day for 28 days via computerized tail-cuff method as previously reported. 22 Mice were placed in individual mouse metabolic cages (Tecniplast, Buguggiate, Italy) with free access to water and food, and at Day 0, 14, 28, urine output and drinking volume were collected and calculated.
Mesenteric Arterial Vascular Tension
Mesenteric arteries were dissected from male EP3 +/+ and EP3 −/− mice after anesthetized with chloral hydrate (10%) intraperitoneally and cut into rings of 1.0 to 1.3 mm long in ice-cold modified Krebs-Ringer bicarbonate buffer. Each segment was suspended between 2 tungsten wires in chambers of a Multi Myograph System (610 M, Danish Myo Technology A/S, Aarhus N, Denmark) for the measurement of isometric force. Each organ chamber was filled with 5 mL of the modified Krebs-Ringer bicarbonate solution maintained at 37 ± 0.5°C and aerated with 95% O 2 -5% CO 2 (pH=7.4). At the beginning of the experiment, each vessel ring was stretched to its optimal resting tension of 1 mN for 30 minutes by stepwise stretching and contracted with 60 mmol/L KCl to test its contractility. Vessels were brought to their optimal resting tension, equilibrated for 30 minutes, and a dose-response to Ang II in vessels was determined. To eliminate the possible involvement of endothelium-derived NO, nitro-L-arginine (100 μmol/L) was included in the medium and present throughout the experiments.
Ca 2+ Imaging in Cultured Vascular Smooth Muscle Cells
Vascular smooth muscle cells (VSMCs) were loaded with the Ca + indicator fluo-4 acetoxymethyl ester (2.5 μmol/L, Molecular Probes) in Tyrode's solution for 5 minutes in the dark at 37°C. After being washed to remove excess indicator, cells were imaged in Tyrode's solution at 23°C using a Zeiss LSM5 Live inverted confocal microscope (Carl Zeiss, Germany) equipped with a ×40 oil immersion objective, at 90 frames/min, with the excitation laser at 488 nm and >505 nm emission.
Myosin Light Chain 20 and Myosin Phosphatase Target Subunit 1 Phosphorylation
Mesenteric arteries were dissected from male mice and rats after being anesthetized with chloral hydrate (10%) intraperitoneally and cut into rings in ice-cold modified Krebs-Ringer bicarbonate buffer. Vessel rings were incubated for 30 minutes in the presence of solvent or DG-041 (1 μmol/L) after being equilibrated in serum-free DMEM for 30 minutes at 37°C. Nitro-L-arginine (100 μmol/L) was included in the medium. Then vessel rings were rapidly taken out and snappy frozen with liquid nitrogen immediately after stimulated by Ang II (1 μmol/L) for 5 minutes. Tissue lysates prepared from the frozen vessels, each containing 20 μg of protein, were subjected to SDS-PAGE and then transferred to polyvinylidene fluoride membrane. Nonspecific binding of antibody was blocked by washing with Trisbuffered saline buffer containing 10% milk for 1 hour. The blot was then incubated with the first antibody of phospho-myosin light chain (MLC) 20 (1:1000 dilution), MLC20 (1:1000 dilution), myosin phosphatase target subunit 1 (MYPT1; 1:1000 dilution), phospho-MYPT1 (Thr696; 1:500 dilution), Rho guanine nucleotide exchange factor (GEF) p115/Lsc (also known as Arhgef-1; 1:500 dilution), respectively, overnight and the secondary antibody for 1 hour. It was developed using the chemiluminescent detection method (Pierce). The protein present on blots was quantified by densitometry using Image J (National Institutes of Health) and normalized to β-actin (1:4000).
Statistical Analysis
Prism (GraphPad, Software Inc, La Jolla, CA) was used for statistical analysis except in the case of chronic Ang II infusion (see below). The results were expressed as means±SE. Data were evaluated by 2-sided Student t test. A P<0.05 was required to reject the null hypothesis. The effect of chronic Ang II treatment on EP3 +/+ and EP3 −/− animals was assessed by comparing the change in SBP from baseline out to 28 days using general linear models with bootstrap covariance accounting for correlation among repeated measures within each mouse, in which the baseline SBP was adjusted as a covariate. Residuals were assessed graphically for normality. These analyses were performed with R-software version 2.9.1 (www.r-project.org), and a 2-sided P<0.05 was required to reject the null hypothesis.
Results
Disruption of the EP3 Receptor Gene Decreases Basal BP
Mean arterial pressure (MAP) was measured in anesthetized EP3 +/+ and EP3 −/− mice. As shown in Figure 1A , baseline MAP was significantly decreased in EP3 −/− mice (EP3 −/− 83.7 ± 1.7 mm Hg versus EP3 +/+ mice 94.0 ± 2.1 mm Hg). Consistent result was observed in conscious state that EP3 −/− mice showed reduced SBP (101.1 ± 1.1 mm Hg) compared with EP3 +/+ mice (105.5 ± 1.6 mm Hg; Figure 1B ).
Deletion of the EP3 Receptor Blunts the Pressor Response to Ang II
Acute infusion of the pressor Ang II increased MAP in EP3 +/+ mice, which was attenuated in EP3 −/− mice. Peak increase in MAP was 90.4 ± 3.0 mm Hg in EP3 −/− mice versus 131.3 ± 3.9 mm Hg in EP3 +/+ mice (data not shown). The net change of MAP in EP3 −/− mice on Ang II infusion was also markedly reduced in EP3 −/− mice (10.5 ± 2.0 mm Hg) versus EP3 +/+ mice (42.1 ± 1.2 mm Hg; Figure 2A ).
A similar effect was observed on chronic Ang II infusion in EP3 −/− mice. As shown in Figure 2B , chronic Ang II infusion increased SBP in both genotypes, whereas compared with EP3 +/+ mice, the EP3 −/− mice had lower SBP without change in heart rate ( Figure 2C ) over time after treatment. Cardiac hypertrophy, as assessed by the heart to body weight ratio, was similar between EP3 +/+ and EP3 −/− mice ( Figure 2D ). Over the 28-day Ang II infusion, average SBP increased to 154.4 ± 3.1 mm Hg in the EP3 +/+ group but only to 138.9 ± 2.2 mm Hg in the EP3 −/− group ( Figure 2B ). The net increase was ≈14 mm Hg lower in EP3 −/− mice (38.6 ± 2.2 mm Hg) compared with EP3 +/+ mice (52.3 ± 3.1 mm Hg; data not shown). During the infusion of Ang II, the increase in SBP was associated with increased urine output and urinary Na + excretion, but no difference was observed between the EP3 +/+ and EP3 −/− groups (Figure 2E and 2F).
EP3 −/− Mice Display a Loss of Vascular Reactivity to EP3 Agonists
The effect of the EP3 gene disruption on vascular reactivity was assessed by infusion of the EP3 receptor-selective agonist M&B28767. The pressor response to M&B28767 was markedly reduced in EP3 −/− mice, increasing MAP by 9.1 ± 1.2 mm Hg versus 35.7 ± 3.4 mm Hg in EP3 +/+ littermates ( Figure  3A) . Similarly, infusion of the dual EP1/3 agonist sulprostone exhibited clear pressor activity in EP3 +/+ mice (28.1 ± 3.4 mm Hg), which was significantly diminished in EP3 −/− mice (5.2 ± 1.4 mm Hg; Figure 3B ). Infusion of the endogenous ligand PGE 2 resulted in an expected depressor effect, which was not different in magnitude between the EP3 −/− and EP3 +/+ groups; however, the EP3 −/− mice appeared to have a more prolonged reduction in MAP as compared with EP3 +/+ mice ( Figure 3C ).
EP3 −/− Mice Exhibit Intact Hemodynamic Responsiveness to Other Vasoactive Agonists
The specificity of the alterations in vascular reactivity was assessed by administration of the α-adrenergic receptor agonist PhE. The peak pressor response to PhE was not significantly different in the EP3 −/− as compared with the EP3 +/+ mice ( Figure 3D) . Similarly, the vasodilator sodium nitroprusside exhibited clear depressor activity in both EP3 +/+ and EP3 −/− mice with no significant difference between the 2 genotypes ( Figure 3E ).
EP3 −/− Mice Mesenteric Arteries Exhibit Reduced Ang II Responsiveness
Reverse transcription polymerase chain reaction analysis revealed that each of the 3 splice variants of mouse EP3 were constitutively expressed in mesenteric arteries and kidney of EP3 +/+ mice ( Figure IB in the online-only Data Supplement), whereas none of the splice variants was detected in the EP3 −/− kidney ( Figure IC in the online-only Data Supplement) and mesenteric arteries (data not shown). Ang II-induced contraction was reduced in the mesenteric arteries from EP3 −/− mice compared with that from EP3 +/+ mice ( Figure  4A ). However, no difference in PhE-evoked vasoconstriction was observed between EP3 +/+ and EP3 −/− mice ( Figure 4B ). In addition, the EP3 selective antagonist DG-041 (1 μmol/L) and L798106 (1 μmol/L) attenuated, whereas its agonist sulprostone (1 μmol/L) enhanced, the Ang II-induced contraction in mesenteric arteries from wild-type mice ( Figure  4C ). Neither the EP3 agonist nor antagonist had effect on PhEevoked vasoconstriction ( Figure 4D ).
Role of EP3 in Ang II-Elicited Phosphorylation of MLC20 in Resistant Vessels
In addition to the Ca 2+ -dependent activation of MLC kinase, Ang II-induced contractility of VSMCs is attenuated by MLC phosphatase. 24 After binding to its G 12/13 -coupled receptor (Ang II type 1 receptor), Ang II activates RhoA/ RhoA kinase signaling pathway via RhoGEFs and causes an inhibitory phosphorylation of MYPT1, the regulatory subunit of MLC phosphatase heterotrimer, leading to vascular contraction. To determine the role of EP3 in Ang II-elicited vasoconstriction, we tested the effect of EP3 inactivation or blockage on the expression of RhoGEFs and the level of phosphorylated MYPT1. Among 3 VSMCspecific RhoGEFs, Arhgef-1 mRNA, but not Arhgef-11 and Arhgef-12, was significantly reduced in the mesenteric arteries from EP3 −/− mice ( Figure 5A and 5B ). In line with the decreased mRNA level, Arhgef-1 protein expression was also reduced in EP3-deficient mesenteric arteries ( Figure  IIA was similarly markedly inhibited by EP3 antagonist DG-041 in rat mesenteric arteries ( Figure 5C and 5D ). In addition, similar results were obtained using porcine coronary arteries, another type of resistant vessel rings ( Figure IV 
Role of the EP3 in Ang II-Elicited Increase in Intracellular Ca 2+ Levels in VSMCs
On binding to its Gq-coupled receptor (Ang II type 1), Ang II stimulates phospholipase C activity and increases intracellular Ca 2+ levels via inositol trisphosphate and protein kinase C-dependent mechanisms. 24 Ca 2+ binds to calmodulin and the Ca 2+ /calmodulin complex then activates MLC kinase to phosphorylate the MLC. To determine the effect of EP3 on Ang II-induced increase in intracellular Ca 2+ levels, we examined the effect of sulprostone or DG-041 on Ang II-induced Ca 2+ Figure 2 . Effect of E-prostanoid (EP) 3 gene disruption on pressor response to angiotensin II (Ang II). A, Reduced pressor effects of Ang II in EP3 −/− mice (n=10) vs EP3 +/+ mice (n=6). Mean arterial pressure (MAP) was monitored by intracarotid catheterization before and during intravenous infusion of Ang II (75 pmol/ kg per minute). The right panels are the summaries of increase in ∆peak MAP (180-280 seconds) during drug infusion. ***P<0.001 vs EP3 +/+ . B, Effect of chronic infusion of Ang II (1000 ng/kg per minutes via osmotic pumps) on systolic blood pressure (SBP) recorded by tail-cuff (n=6 per group). Ang II infusion resulted in significant increase in blood pressure in both EP3 +/+ and EP3 −/− mice, with more profound increase in EP3 +/+ mice than in EP3 −/− mice, ****P<0.0005 vs EP3 +/+ . The right panels are the average changes in SBP during Ang II chronic infusion in EP3 +/+ and EP3 −/− mice. ***P<0.001 vs EP3 +/+ . C, Effect of chronic infusion of Ang II on heart rate. There was no difference between EP3 +/+ and EP3 −/− mice in heart rate before or after Ang II infusion. D, Effect of chronic infusion of Ang II on heart weight. Cardiac hypertrophy, assessed by heart weight/body weight, between EP3 +/+ and EP3 −/− was similar after chronic Ang II infusion. *P<0.05, EP3 +/+ Control vs EP3 +/+ Ang II group; ##P<0.01, EP3 −/− Control vs EP3 −/− Ang II group, n=5. E, Average changes in 24-hour urine output in EP3 +/+ and EP3 −/− mice at day 0, day 14, and day 28 during chronic Ang II infusion. Ang II infusion caused similar diuretic effect in both genotypes. Urine output was slightly lower in EP3 −/− mice than in EP3 +/+ mice, but the difference was not significant. *P<0.05, **P<0.01 vs the baseline levels (day 0) in EP3 +/+ group, n=6; #P<0.05, ##P<0.01 vs the baseline levels (day 0) in EP3 −/− group, n=6. F, 24-hour urinary sodium excretion in EP3 +/+ and EP3 −/− mice during chronic Ang II infusion. Similar natriuretic effect was observed in both EP3 +/+ and EP3 −/− mice after Ang II infusion. Urinary sodium excretion was slightly lower in EP3 −/− mice than in EP3 +/+ mice, but the difference was not significant. *P<0.05, **P<0.01 vs the baseline levels (day 0) in EP3 +/+ group, n=6; # P<0.05, ## P<0.01 vs the baseline levels (day 0) in EP3 −/− group, n=6. December 2012 increase. Incubation of VSMCs with sulprostone (10 μmol/L) for 30 minutes potentiated the Ang II-induced increase in intracellular Ca 2+ levels ( Figure 6A and 6B) . Compared with Ang II, sulprostone at high dose (10 μmol/L) alone only slightly increased Ca 1+ levels ( Figure VA in the online-only Data Supplement). In contrast, the EP3 antagonist DG-041 pretreatment for 30 minutes concentration-dependently inhibited Ang II-evoked Ca 2+ signal ( Figure 6C and 6D) , with little effect on calcium levels in PhE-treated cells ( Figure VB Discussion PGE 2 has been demonstrated to act as either a pressor or depressor depending on the EP receptor activated. 19, [25] [26] [27] [28] [29] [30] [31] [32] The balance of pressor and depressor receptors activated by PGE 2 plays an important role in the overall regulation of BP, and a functional imbalance of EP receptors may be an important mechanism in the development of essential hypertension. The current study demonstrated that targeted gene disruption of the EP3 receptor resulted in lower BP at baseline, in agreement with our earlier findings that EP3 was an important contributor to the pressor response to PGE 2 . 22 Our studies also found that the EP3 receptor sensitized the resistant vessels/VSMCs to the actions of Ang II, suggesting that the EP3 receptor may contribute to increased BP in Ang II-dependent hypertension.
The fall in baseline BP in the EP3 −/− mice suggested that EP3 receptor activation played a tonic role in BP homeostasis. This was further supported by the findings that acute infusion of the EP3 agonists resulted in a lesser increase in BP in EP3 −/− mice. However, on infusion of PGE 2 , an endogenous ligand for all 4 EP receptors, no difference in the magnitude of the depressor response was observed in EP3 −/− mice, suggesting that the vasodepressor response to PGE 2 , which is predominantly mediated by the activation of the stimulatory G protein-coupled EP2 and EP4, is intact.
In EP3 −/− mice, there was also a striking loss of the acute pressor response specific to Ang II. Consistent with the blunted pressor effects of acute infusion of Ang II, chronic administration of Ang II also resulted in less of an increase of SBP in EP3 −/− mice. Furthermore, the changes in renal function did not appear to contribute to the difference in BP between EP3 +/+ and EP3 −/− mice, because no significant alteration was observed in urine volume and sodium excretion between 2 genotypes. Together, these results suggest that the synergistic effect of EP3 on the Ang II pressor response is a direct effect in the vasculature.
Three additional independent lines of study support the hypothesis that the effect of EP3 on Ang II signaling is at the level of resistant vessels and is mediated at least in part by direct action on the contractility of vascular smooth muscle. First, the contraction of the mesenteric artery induced by Ang II was reduced in EP3 −/− mice. In addition, the EP3 agonist potentiated, whereas its antagonist attenuated, Ang II-evoked mesenteric arterial contractility. Second, Ang IIinduced phosphorylation of MLC20 and MYPT1 were inhibited by DG-041, and RhoGEF 1 (Arhgef-1), an important GDP-GTP exchange factor specifically responsible for Ang II-induced RhoA activation, was significantly suppressed in EP3 −/− mouse mesenteric arteries. Finally, the increase of Ang II-evoked intracellular calcium levels in VSMCs was attenuated by the EP3 antagonist DG-041 but enhanced by the EP3 agonist sulprostone. It is well known that the contractility of vascular smooth muscle is potentiated by phosphorylation of MLC20 via Ca 2+ / calmodulin-activated MLC kinase and reduced by dephosphorylation of MLC20 via MLC phosphatase. Ang II-induced activation of its Gq-coupled receptor causes a rise of Ca 2+ levels to initiate Ca 2+ /calmodulin/MLC kinase pathway, whereas activation of its G 12/13 -coupled receptor potentiates Ca 2+ sensitivity by increasing activity of RhoGEF, activating Rho/ Rho-kinase signaling and then inhibiting phosphorylation of MYPT1, the regulatory subunit of MLC phosphatase heterotrimer. 33, 34 Previous studies have demonstrated that in addition to inhibitory G protein signaling causing a decrease in cAMP levels, the EP3 receptor may also mobilize intracellular calcium. 17, 35, 36 It is also found that the EP3 agonist sulprostoneinduced contraction of guinea-pig thoracic aorta may involve Ca 2+ influx via L-type Ca 2+ channels. 37 We showed that the EP3 receptor agonist sulprostone potentiated Ang II-evoked Ca 2+ mobilization and the EP3 antagonist DG-041 attenuated Ang II-stimulated phosphorylation of MLC20 and MYPT1, which suggested that the EP3 receptor may synergize Ang II-induced vasoconstriction. Among 3 RGS-containing RhoGEFs (Arhgef-1, -11, and -12), important GDP-GTP exchange factors specifically responsible for Ang II-induced RhoA activation in VSMCs, [38] [39] [40] only Arhgef-1 expression was significantly reduced in EP3 −/− mesenteric arteries. The reason why the EP3 receptor selectively affects Arhgef-1 expression is currently unknown. However, given the critical role of RGS-containing RhoGEFs in linking Ang II type 1 to RhoA activation, it is expected that reduction of Arhgef-1 expression would result in diminished phosphorylation of MLC20 and MYPT1 in EP3 −/− arteries exposed to chronic Ang II treatment. PGE 2 is a major cyclooxygenase product of vascular smooth muscle where Ang II stimulates its synthesis. [41] [42] [43] Recent studies suggest that cyclooxygenase 1 activity is critical for the pressor response to Ang II in both acute and chronic Ang II-dependent models, 44, 45 and Ang II-stimulated synthesis of cyclooxygenase 1-derived PGE 2 activates the EP1 receptor to promote Ang II-dependent hypertension. 18 The present study further provides evidence that the EP3 receptor may also represent as a tonic vasoconstriction mediator, which acts synergistically with Ang II to increase BP. Because intrarenal and extrarenal Ang II type 1 receptors play nonredundant pressor roles in Ang II-induced hypertension, 46 the present findings also support the possibility that the combination of Ang II receptor blockers and the EP3 antagonists may represent a novel therapeutic strategy for the treatment of hypertension ( Figure VI in the online-only Data Supplement). Moreover, because both the EP1 and EP3 receptors are vasoconstrictive, it would be interesting to determine whether blockade of both receptors is additive in reducing BP at baseline or in Ang II-dependent hypertension. This important issue could be addressed in a mouse line deficient for both EP1 and EP3 genes, and it warrants further investigation.
One unexpected finding from our study is that although EP3 −/− mice showed significantly attenuated Ang II-induced hypertension, no alleviated cardiac hypertrophy was observed. One possible explanation for this discrepancy is that in addition to a direct growth promoting effect on cardiac myocytes and fibroblasts, Ang II may synergize with the sympathetic nervous system, aldosterone, inflammation, and oxidative stress systemically or locally to drive cardiac hypertrophy and fibrosis in the face of high BP and increased heart afterload. 47,48 Figure 6 . Effect of E-prostanoid (EP) 3 agonist or antagonist on angiotensin II (Ang II)-elicited increase in intracellular Ca 2+ in vascular smooth muscle cells (VSMCs). A, Potentiation of Ang II-induced intracellular Ca 2+ increase in VSMCs by sulprostone. VSMCs were preincubated with the EP3 agonist sulprostone for 30 minutes, at the doses of 1 μmol/L and 10 μmol/L, respectively. B, Ratio of peak-to-basal change (sF/F0) in Fluo-4AM fluorescence intensity in VSMCs treated with sulprostone and Ang II (1 μmol/L), **P<0.01 vs. Control group, n=7 in each group. C, Dose-dependent inhibitory effect of DG-041 on intracellular Ca 2+ flux induced by Ang II. VSMCs were pretreated with the EP3 antagonist DG-041 for 30 minutes at the doses of 0 μmol/L, 0.1 μmol/L, 1 μmol/L, and 10 μmol/L, respectively. D, Ratio of peak-to-basal change (F/F0) in Fluo-4AM fluorescence intensity in VSMCs treated with DG-041 and Ang II (1 μmol/L), *P<0.05; ### P<0.001 vs. Control group, n=7 per group.
Because PGE 2 has been found to be involved in the regulation of inflammation, aldosterone release, sympathetic activation, and oxidative stress, 49, 50 EP3 gene deficiency may alter these biological processes and affect Ang II-elicited cardiac hypertrophy. However, given that multiple splicing variants of the EP3 receptor exist, 51 it is hard to predict the exact cardiac phenotypes in mice with all EP3 receptor isoform deleted. Therefore, the effect of the EP3 receptor on Ang II-dependent cardiac remodeling appears to be very complicated, and the exact mechanism by which Ang II induces similar extent of cardiac hypertrophy phenotype in wild-type and EP3 −/− mice requires further investigation.
In summary, the EP3 receptor is a vasoconstriction mediator and its inactivation attenuates Ang II-induced hypertension. It contributes to Ang II-dependent hypertension at least partially via enhancing intracellular calcium concentration and Ca 2+ sensitivity. Selective targeting of the EP3 receptor may represent a potential therapeutic target for the treatment of hypertension.
